Bookrunners BofA Merrill Lynch, Cowen, Piper Jaffray assist with deal
By Devika Patel
Knoxville, Tenn., July 20 – Audentes Therapeutics, Inc. said on Tuesday that it priced its $75 million initial public offering of stock with an $11.25 million greenshoe. The deal was announced Jan. 4.
The company will sell 5 million common shares at $15.00 per share.
BofA Merrill Lynch, Cowen and Co. and Piper Jaffray are the bookrunners.
Proceeds will be used for clinical trials, preclinical development, working capital and other general corporate purposes.
The biotechnology company is based in San Francisco. The company expects its shares will trade on the Nasdaq under the symbol “BOLD.”
| Issuer: | Audentes Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $75 million
|
| Greenshoe: | $11.25 million, or 750,000 shares
|
| Shares: | 5 million
|
| Price: | $15.00
|
| Warrants: | No
|
| Bookrunners: | BofA Merrill Lynch, Cowen and Co. and Piper Jaffray
|
| Co-manager: | Wedbush PacGrow
|
| Announcement date: | Jan. 4
|
| Pricing date: | July 19
|
| Stock exchange: | Nasdaq: BOLD
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
